Recent Updates
Recently added Catalysts

Spero Therapeutics, Inc.

SPRO
UndervaluedBiotech · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$1.14
▼ -0.01 · -0.85%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SPRO financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.0852W HIGH $3.08
Volume
719.79 K
Value Traded
436.39 K
Short % Float
2.27%
-4.2%Week
-2.56%1 Month
-45.71%3 Month
-57.3%6 Month
-80.69%5 Year
-79.17%All Time

Cash Data

Unlock SPRO cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
66.39 M
EPS (TTM)
-0.38
P/E Ratio
-
Ent. Value
15.61 M
Total Shares
58.23 M
Float Shares
42.98 M
Insiders
26.19%
Institutions
15.64%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every SPRO catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SPRO Catalyst Timeline

Dated clinical, regulatory and corporate events for Spero Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Spero Therapeutics, Inc.

504Total events
11Upcoming
126Tier-1 (high impact)
2017 to 2029Coverage

Upcoming catalysts 2

T2Product Launch
Subscribe to view catalyst details
UtebziApproved
T2Trial Initiation
Subscribe to view catalyst details
SP001

Event history 50

●Equity OfferingCorporate
Inducement grants of 233,000 RSUs and 323,000 stock options approved for new employees
source ↗
●Quarterly UpdateCorporate
Second quarter 2026 financial results
source ↗
●Oral PresentationPresentation
Conference call and webcast to discuss Q2 results
source ↗
●Management ChangeCorporate
Debra Jeske Zack appointed Chief Medical Officer
source ↗
▲Partnership / LicenseSP001Corporate
Exclusive license agreement between Spero and Innovent for SP001 (IBI355)
source ↗
▲Partnership / LicenseIBI355Corporate
Exclusive license agreement for IBI355 (SP001) between Innovent and Spero
source ↗
▲Equity OfferingCorporate
$105 million non-recourse non-dilutive royalty financing from HCRx backed by Utebzi milestones and royalties
source ↗
▲Runway Guidance UpdateCorporate
Cash runway guidance updated into second half of 2029
source ↗
▲Partnership / LicenseSP001Corporate
Exclusive license agreement with Innovent Biologics for SP001
source ↗
▲Debt Royalty FinancingCorporate
Closed $105 million non-recourse, non-dilutive royalty financing with HCRx
source ↗
Unlock the full SPRO catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SPRO actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-18tebipenem HBr PDUFA Date ApprovedPDUFA
Unlock 13 more SPRO historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D39 / 100
Pipeline Score
$65M
Pipeline Value
$47M
Commercial Value
Undervalued
Valuation Signal
2
Drugs Scored
3.1x
rNPV / MCap
Top 42%
Micro Cap
(rank 277 of 658)
Percentile Rank
Spero Therapeutics, Inc. faces pipeline headwinds (39/100), with $516M risk-adjusted pipeline value, led by SPR206 in Renal Impairment (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $47M x 1.0 = $47M
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SPR206 Small moleculeCompletedNCT04865393Renal ImpairmentPhase 1 COMPLETED 37Dec 6, 2021
Unlock the SPRO pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SPRO program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
tebibpenem HBr complicated urinary tract infections (cUTIs)Phase 32025-10-21tebibpenem HBr success rate: 58.5% (261/446 participants); imipenem cilastatin success rate: 60.2% (291/483 participants); adjusted treatment difference: −1.3%; 95% CI: −7.5%, 4.8%Read MorePIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)Read More
Scroll for more · summaries link to the source press release
Unlock every SPRO trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SPRO insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Rajavelu EstherOfficer (See Remarks)Sell -25,240 986,851 held$2.51 05/04/2026
Unlock the full SPRO insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in SPRO

Fund % of Portfolio Current MV Shares Owned Activity
DAFNA Capital Management LLC 0 % 90.00 K 125.00 K
Unlock every fund holding SPRO
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SPRO
Shares held by hedge funds each quarter, and who bought or sold.

SPRO Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2027-01-15
Unlock SPRO option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SPRO option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SPRO options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SPRO ranks across every disease it competes in

Competitive Position is a premium feature
See how SPRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SPRO News

SPRO
Oct 2, 2026
SPROGeneral

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics announced the approval of inducement grants for new employees, including 233,000 restricted stock units and 323,000 stock options. These grants are part of the 2019 Inducement Equity Incentive Plan, aimed at attracting talent under Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs will vest over time, contingent on continued employment.

Read more →
SPRO
Sep 3, 2026
SPROGeneral

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics announced the approval of an inducement grant for new employees, consisting of 102,000 restricted stock units and 67,600 stock options. This grant is part of their 2019 Inducement Equity Incentive Plan and aims to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The options and RSUs are set to vest over several years, contingent on continued employment.

Read more →
SPRO
Sep 2, 2026
SPROConferences/Events

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Spero Therapeutics, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 28th Annual Global Healthcare Conference in New York City from September 14th to 16th, 2026. CEO Esther Rajavelu will lead the presentation, and the leadership team will be available for one-on-one meetings. The company focuses on developing next-generation medicines for serious immune-mediated diseases.

Read more →
SPRO
Aug 12, 2026
SPROGeneral

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics reported its second quarter 2026 results, highlighting significant milestones including FDA approval for Utebzi, a new oral antibiotic. The company also secured $105 million in financing and entered a license agreement for SP001, a promising monoclonal antibody. Despite these achievements, Spero faced a net loss and no revenue for the quarter.

Read more →
SPRO
Aug 4, 2026
SPROConferences/Events

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Spero Therapeutics will report its financial results for Q2 2026 on August 12, 2026. The company will host a conference call at 5:00 PM EDT to discuss these results and provide updates on its business and pipeline. Spero is focused on developing innovative treatments in immunology and inflammation.

Read more →
SPRO
Jul 27, 2026
SPROGeneral

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Spero Therapeutics has appointed Dr. Debra Jeske Zack as Chief Medical Officer, enhancing its clinical leadership team. Dr. Zack, with over 25 years of experience in immunology and rheumatology, will lead the clinical strategy for SP001, a promising therapy for IgG4-related disease. The company aims to address significant unmet medical needs through this innovative treatment.

Read more →
SPRO
Jul 14, 2026
SPROGeneral
▼ -22%on this news

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Spero Therapeutics has announced a $105 million non-recourse financing deal to support the Phase 2 development of its immunology drug candidate SP001. The financing is backed by future milestones and royalties from Utebzi, which has recently received FDA approval. This transaction strengthens Spero's financial position and extends its cash runway into the second half of 2029.

Read more →
SPRO
Jul 14, 2026
SPROPhases
▼ -22%on this newsshared move

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Innovent Biologics and Spero Therapeutics have entered an exclusive licensing agreement for IBI355, a third-generation anti-CD40L antibody. Spero will develop IBI355 globally, excluding Greater China, where Innovent retains rights. Both companies plan to initiate Phase 2 trials for IgG4-related disease and Sjögren's disease by early 2027. The deal is valued at approximately $1.1 billion.

Read more →
SPRO
Jul 14, 2026
SPROPhases
▼ -22%on this newsshared move

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics and Innovent Biologics have entered an exclusive licensing agreement for SP001, a third-generation anti-CD40L antibody. Spero will develop SP001 globally, excluding Greater China, and plans to initiate a Phase 2 trial for IgG4-related disease in Q2 2027. Innovent will also start a Phase 2 trial for Sjögren’s disease in early 2027. The deal includes an upfront payment and potential milestone payments totaling approximately $1.1 billion.

Read more →
SPRO
Jun 18, 2026
SPROFDA Updates
▲ +8.1%on this news

EX-99.1

Spero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare diseases. The press release discusses forward-looking statements regarding the potential approval of tebipenem HBr and associated risks, including regulatory delays and reliance on third parties.

Read more →
SPRO
Jun 17, 2026
SPROFDA Updates
▼ -6.4%on this news

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

The FDA has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs). This approval follows the successful PIVOT-PO trial, demonstrating non-inferiority to intravenous treatments. Utebzi aims to provide an effective outpatient treatment option, addressing the significant healthcare burden posed by cUTIs and antibiotic resistance.

Read more →
SPRO
May 13, 2026
SPROFDA Updates

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics reported its first quarter 2026 results, highlighting the ongoing FDA review of its New Drug Application for tebipenem HBr, aimed at treating complicated urinary tract infections. The company maintains a cash runway into 2028, despite a net loss of $7.2 million for the quarter. The Phase 3 trial for tebipenem HBr showed promising results, positioning it as a potential oral alternative to IV treatments.

Read more →
SPRO
May 5, 2026
SPROGeneral

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Spero Therapeutics has announced it will report its first quarter 2026 financial results and provide a business update on May 13, 2026. The report will be released after market close, and the company has stated it will not hold a conference call. This reflects Spero's commitment to keeping stakeholders informed.

Read more →
SPRO
Mar 27, 2026
SPROFDA Updates

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant advancements in the tebipenem HBr program for cUTI. The company completed a global Phase 3 trial and resubmitted its NDA, with an FDA decision expected in late June. Spero is focused on fulfilling its licensing agreement with GSK while exploring new clinical-stage opportunities.

Read more →
SPRO
Mar 18, 2026
SPROGeneral

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

Spero Therapeutics announced that it will report its financial results for the fourth quarter and full year 2025 on March 26, 2026, after market close. The company focuses on developing treatments for rare diseases and areas with significant unmet medical needs. No conference call will be held to discuss these results. The announcement reflects Spero's ongoing commitment to transparency with its investors.

Read more →
SPRO
Dec 22, 2025
SPROFDA Updates

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

Spero Therapeutics announced that its partner GSK has resubmitted a New Drug Application for tebipenem HBr to the FDA for treating complicated urinary tract infections. This resubmission follows positive results from the Phase 3 PIVOT-PO trial, which was halted early due to efficacy. Spero will receive a $25 million milestone payment upon submission.

Read more →

About Spero Therapeutics, Inc.

Cambridge, MA 25 employees sperotherapeutics.com
Headquarters675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02139
BIOPHARMAWATCH ELITE PLUS
Trade the next SPRO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime